BVCF Management, a private equity firm, and Hyfinity Investments, a venture capital firm, led a $57m Series C funding round in Oculis, a biopharmaceutical company. Additional investors include VI Partners, Wille, Bay City Capital, Brunnur Ventures, EarlyBird, Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, and Silfurberg. “We are entering an exciting new phase of our journey as we advance towards late-stage development and prepare the organization to successfully bring novel therapies to millions of patients worldwide. We feel fortunate to be welcoming such high caliber and diversified new investors and are delighted with the continued support of our existing investors – the quality and breadth of our shareholder base is testament to the exceptional science, groundbreaking development, and the multiple opportunities we have to transform positively patients’ lives globally. Their support and involvement will be crucial for Oculis as we continue to build a global ophthalmology company with a footprint in key markets. Further, on behalf of our Board, investors and management team, I would like to thank Dr. Loftsson and Dr. Weber for their positive contributions to and impact on Oculis through their services on the Board," Riad Sherif, Oculis CEO.